GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » EPS (Diluted)

Biovica International AB (OSTO:BIOVIC B) EPS (Diluted) : kr-2.57 (TTM As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB EPS (Diluted)?

Biovica International AB's Earnings per Share (Diluted) for the three months ended in Jan. 2024 was kr-0.44. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was kr-2.57.

Biovica International AB's EPS (Basic) for the three months ended in Jan. 2024 was kr-0.44. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2024 was kr-2.57.

Biovica International AB's EPS without NRI for the three months ended in Jan. 2024 was kr-0.44. Its EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2024 was kr-2.57.

During the past 3 years, the average EPS without NRIGrowth Rate was -35.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -24.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Biovica International AB's highest 3-Year average EPS without NRI Growth Rate was -11.70% per year. The lowest was -54.00% per year. And the median was -27.95% per year.


Biovica International AB EPS (Diluted) Historical Data

The historical data trend for Biovica International AB's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB EPS (Diluted) Chart

Biovica International AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only -1.22 -1.28 -1.38 -2.09 -3.20

Biovica International AB Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 -0.87 -0.70 -0.56 -0.44

Competitive Comparison of Biovica International AB's EPS (Diluted)

For the Biotechnology subindustry, Biovica International AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biovica International AB's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biovica International AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where Biovica International AB's PE Ratio falls into.



Biovica International AB EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Biovica International AB's Diluted EPS for the fiscal year that ended in Apr. 2023 is calculated as

Diluted EPS (A: Apr. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-110.492-0)/34.461
=-3.21

Biovica International AB's Diluted EPS for the quarter that ended in Jan. 2024 is calculated as

Diluted EPS (Q: Jan. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-27.343-0)/62.816
=-0.44

EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biovica International AB  (OSTO:BIOVIC B) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biovica International AB EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Biovica International AB's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biovica International AB (OSTO:BIOVIC B) Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB (OSTO:BIOVIC B) Headlines

No Headlines